Top

Published in:

01-10-2020 | Breast Cancer | Editorial

Are we ready to use TMB in breast cancer clinical practice?

Authors: Sara Ravaioli, Francesco Limarzi, Maria Maddalena Tumedei, Michela Palleschi, Roberta Maltoni, Sara Bravaccini

Published in: Cancer Immunology, Immunotherapy | Issue 10/2020

Abstract

We discussed the potentialities of tumor mutation burden (TMB) as a predictive marker for immunotherapy in breast cancer, also highlighting the limits that have hindered its introduction in the clinical practice. Although some studies have demonstrated the possibility to select patients more responsive to immune-checkpoint inhibitors by evaluating TMB, some issues emerged regarding the complexity of the methodologies for its determination, the costs of the analysis, and the necessity to improve the TMB determination with that of neoantigen identification.

Chan TA, Yarchoan M, Jaffee E et al (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 30(1):44–56. https://doi.org/10.1093/annonc/mdy495CrossRefPubMed

Meléndez B, Van Campenhout C, Rorive S et al (2018) Methods of measurement for tumor mutational burden in tumor tissue. Transl Lung Cancer Res 7:661–667. https://doi.org/10.21037/tlcr.2018.08.02CrossRefPubMedPubMedCentral

Friedlaender A, Nouspikel T, Christinat Y et al (2020) Tissue-plasma TMB comparison and plasma TMB monitoring in patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitors. Front Oncol 10:142. https://doi.org/10.3389/fonc.2020.00142CrossRefPubMedPubMedCentral

Ou S-HI, Nagasaka M, Zhu VW (2018) Liquid biopsy to identify actionable genomic alterations. Am Soc Clin Oncol Educ B. https://doi.org/10.1200/EDBK_199765CrossRef

Narayan P, Wahby S, Gao JJ et al (2020) FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1. Clin cancer Res Off J Am Assoc Cancer Res 26:2284–2289. https://doi.org/10.1158/1078-0432.CCR-19-3545CrossRef

Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108–2121. https://doi.org/10.1056/NEJMoa1809615CrossRefPubMed

Palleschi M, Maltoni R, Sarti S et al (2020) Immunotherapy: the end of the “dark age” for metastatic triple-negative breast cancer? Breast J. https://doi.org/10.1111/tbj.13662CrossRefPubMed

Rizvi H, Sanchez-Vega F, La K et al (2018) Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol 36:633–641. https://doi.org/10.1200/JCO.2017.75.3384CrossRefPubMedPubMedCentral

Mei P, Freitag CE, Wei L et al (2020) High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas. Diagn Pathol 15:50. https://doi.org/10.1186/s13000-020-00971-7CrossRefPubMedPubMedCentral

10.

Chumsri S, Sokol ES, Soyano-Muller AE et al (2020) Durable complete response with immune checkpoint inhibitor in breast cancer with high tumor mutational burden and APOBEC signature. J Natl Compr Canc Netw. https://doi.org/10.6004/jnccn.2020.7543CrossRefPubMed

Title: Are we ready to use TMB in breast cancer clinical practice?
Authors: Sara Ravaioli
Francesco Limarzi
Maria Maddalena Tumedei
Michela Palleschi
Roberta Maltoni
Sara Bravaccini
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Checkpoint Inhibitors
Biomarkers
Published in: Cancer Immunology, Immunotherapy / Issue 10/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02682-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2020

Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation

PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas

Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer

A TLR4–TRIF-dependent signaling pathway is required for protective natural tumor-reactive IgM production by B1 cells

Observations on neuroimmunomodulation as a novel therapeutic strategy in metastasis

Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer